Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
FSD Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
HUGE
New York
8731
https://www.fsdpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for FSD Pharma Inc
FSD Pharma Provides Update from Celly Nu’s Partnership with Six+One for unbuzzd(TM)
- Apr 25th, 2024 11:47 am
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
- Apr 22nd, 2024 12:00 pm
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
- Apr 17th, 2024 12:00 pm
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
- Apr 15th, 2024 12:00 pm
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Apr 8th, 2024 2:55 am
FSD Pharma Announces Filing of Year-End 2023 Results
- Apr 2nd, 2024 2:00 am
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
- Mar 27th, 2024 12:00 pm
FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
- Mar 11th, 2024 12:00 pm
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
- Mar 5th, 2024 1:00 pm
FSD Pharma Announces Debt Settlement
- Feb 28th, 2024 1:00 pm
FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)
- Feb 26th, 2024 1:00 pm
FSD Pharma Announces US ATM Offering
- Feb 17th, 2024 12:50 am
Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million
- Feb 6th, 2024 12:00 pm
FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates
- Jan 29th, 2024 9:30 pm
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot
- Jan 16th, 2024 12:30 pm
GBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case
- Jan 11th, 2024 6:10 pm
FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC
- Dec 23rd, 2023 12:45 am
FSD Pharma Inc. Announces Closing of Private Placement
- Dec 5th, 2023 2:00 pm
FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement
- Nov 30th, 2023 1:30 pm
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness
- Nov 28th, 2023 2:00 pm
Scroll